Dipeptidylpeptidase (dpp)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sfrp)-5 which is decreased in severe covid-19 disease

HIGHLIGHTS

• who: Juliane Brandes from the InstitutUniversity Medical have published the research: Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease, in the Journal: Scientific Reports Scientific Reports
• what: The aim of this study was to examine, if DPP4i exert antiinflammatory effects in treated T2D subjects which might explain the beneficial effects in Covid-19 patients. In a next set of experiments, the authors aimed to examine, which specific cell type in adipose_tissue is important for sFRP5 synthesis and release . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.